Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of domestic versus imported ceftazidime + avibactam sodium in healthy Chinese adults
ChiCTR2400083867Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime and avibactam in Enterobacteriaceae infection, Intra-abdominal infection (IAI), complicated urinary tract infection (cUTI) and 1 more (2 arms), sponsored by Tongji Hospital. Primary endpoint: Pharmacokinetic parameters. Planned start May 2024; status: not yet recruiting.
02
Drugs
ceftazidimeavibactam
03
Conditions
Enterobacteriaceae infectionIntra-abdominal infection (IAI)complicated urinary tract infection (cUTI)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on ChiCTR2400083867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083867.